Heparin accelerates the inhibition of cathepsin G by mucus proteinase inhibitor: potent effect of O-butyrylated heparin

Heparin tightly binds cathepsin G and so protects the enzyme from inhibition by alpha1-antichymotrypsin, alpha1-proteinase inhibitor and eglin c, three proteins which do not bind heparin [Ermolieff J., Boudier C., Laine A., Meyer B. and Bieth J.G. (1994) J. Biol. Chem. 269, 29502-29508]. Here we show that heparin no longer protects cathepsin G from inhibition when the enzyme is reacted with mucus proteinase inhibitor (MPI), a heparin-binding protein. Heparin fragments of Mr=4500 and 8100 and O-butyrylated heparin of Mr=8000 form tight complexes with cathepsin G (Kd=0.5-2.2 nM) and MPI (Kd=0. 4-0.8 muM) and accelerate the MPI-promoted inhibition of cathepsin G by a factor of 17-26. They also accelerate the inhibition of neutrophil elastase and pancreatic chymotrypsin. The rate acceleration is due to the binding of heparin to MPI. Butyrylation of heparin slightly decreases its affinity for cathepsin G and MPI but sharply decreases the ionic interactions between the positively charged proteins and the negatively charged polyanion. The butyrylated heparin derivative is the best rate accelerator: it increases the rate constant for the MPI-induced inhibition of cathepsin G and elastase by factors of 26 and 23, respectively. This, together with the fact that it has a good bioavailability and a very low anticoagulant activity, suggests that it might be an adjuvant of MPI-based therapy of cystic fibrosis.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Heparin and O-butyrylated heparin bind cathepsin G and mucus proteinase inhibitor, accelerating MPI-mediated inhibition of cathepsin G 17- to 26-fold; the butyrylated derivative also accelerates elastase inhibition 23-fold and has very low anticoagulant activity.

Explore how this research connects to clinical practice

More peer-reviewed studies in Salivary Pharmacology.

• Medicinal leeches and hirudotherapy — Gödekmerdan A et al. (2011)
• PEROXIDATION OF SALIVA LIPIDS IN PATIENTS WITH POSTCOVID SYNDROME DURING HIRUDOTHERAPY — Serikbayeva S et al. (2024)
• Medicinal leech therapy in pain syndromes: a narrative review — Koeppen D, Aurich M, Rampp T (2014)
• Immunomodulatory effects of medicinal leech saliva extract on in vitro activated macrophages — Ayhan H et al. (2024)
• Proteinase inhibitors from the medicinal leech Hirudo medicinalis — Baskova I, Zavalova L (2001)
• Polyfunctionality of destabilase, a lysozyme from a medicinal leech — Baskova I, Zavalova L (2008)
• Make it double: identification and characterization of a Tandem-Hirudin from the Asian medicinal leech Hirudinaria manillensis — Lukas P et al. (2022)
• Use of the medicinal leech in the treatment of ear diseases — Seleznev K et al. (1992)
• Recombinant Destabilase from Hirudo medicinalis Is Able to Dissolve Human Blood Clots In Vitro — Bobrovsky P et al. (2021)
• Effects of Carbon Nanotube Environmental Dispersion on an Aquatic Invertebrate, Hirudo medicinalis — Girardello R et al. (2015)

Browse all ASH-analysed research →